Targeting filamin B induces tumor growth and metastasis via enhanced activity of matrix metalloproteinase-9 and secretion of VEGF-A

S Bandaru1, A-X Zhou1, P Rouhi2, Y Zhang2, MO Bergo3, Y Cao2,4 and LM Akyürek1,5

Filamins regulate cell locomotion and associate with diverse signaling molecules. We have recently found that targeting filamin A (FLNA) reduces RAS-induced lung adenocarcinomas. In this study, we explored the role of another major filamin isoform, filamin B (FLNB), in tumor development. In contrast to FLNA, we report that targeting FLNB enhances RAS-induced tumor growth and metastasis which is associated with higher matrix metalloproteinase-9 (MMP-9) and extracellular signal-regulated kinase (ERK) activity. Flnb deficiency in mouse embryonic fibroblasts results in increased proteolytic activity of MMP-9 and cell invasion mediated by the RAS/ERK pathway. Similarly, silencing FLNB in multiple human cancer cells increases the proteolytic activity of MMP-9 and tumor cell invasion. Furthermore, we observed that Flnb-deficient RAS-induced tumors display more capillary structures that is correlated with increased vascular endothelial growth factor-A (VEGF-A) secretion. Inhibition of ERK activation blocks phorbol myristate acetate-induced MMP-9 activity and VEGF-A secretion in vitro. In addition, silencing FLNB in human ovarian cancer cells increases secretion of VEGF-A that induces endothelial cells to form more vascular structures in vitro. We conclude that FLNB suppresses tumor growth and metastasis by regulating the activity of MMP-9 and secretion of VEGF-A which is mediated by the RAS/ERK pathway.

Received 15 May 2014; revised 29 July 2014; accepted 4 August 2014

INTRODUCTION

Increased tumor growth and metastasis during tumor progression is highly dependent on oncogenic angiogenesis and degradation of the extracellular matrix. The ectopic expression of metalloproteinases (MMPs) and pro-angiogenic growth factors including vascular endothelial growth factor (VEGF) is a common phenomenon in multiple cancers. Drugs counteracting these processes such as antiangiogenic drugs and MMP inhibitors have been intensively studied as cancer therapeutics.1,2 However, the clinical usage of these drugs is currently limited by the moderate beneficial effects or high toxicities.1,2 The identification of novel molecules that regulate tumor angiogenesis and matrix invasion will therefore provide valuable mechanistic insights, thus promoting the design of new anticancer therapies.

Filamins (FLNs) are large actin-binding proteins consisting of three conserved isoforms in mammals: FLNA, FLNB and FLNC. FLNs crosslink cortical cytoplasmic actin filaments into a dynamic three-dimensional structure and anchor the actin network onto the plasma adhesion receptors such as integrins, thus regulating the dynamic changes of the actin cytoskeleton in response to extracellular signals. On the other hand, FLNs also regulate the activity of integrins and their ligand binding. Moreover, FLNs interact with diverse cellular proteins, including transmembrane receptors, ion channels, signaling molecules and transcription factors that may directly or indirectly regulate cellular response and cell motility.3-5 Recently, the aberrant expression or intracellular localization of FLNA has been clinically associated with the aggression of multiple cancers, including hepatic cholangiocarcinoma,6 pancreatic cancer,7 prostate cancer,8 metastatic breast cancer and high-grade astrocytoma.9 We and others have found that targeting FLNA reduces RAS-induced lung tumors in mice10 and Flna deficiency causes significant reduction in lung, splenic and systemic metastasis of tumor cells in nude mice.11 This suggests that FLNA positively regulates tumor progression either through its essential function in cell locomotion or its scaffolding functions in cell signaling. Because of its profound effect on cancers, FLNA seems to be an important disease marker in certain cancers and a potential therapeutic target.8,9,12,13

FLNB shares 80% amino acid sequence homology with FLNA and the potential functional compensation between the two isoforms has been under recent debate.14,15 Despite the high homology between the two isoforms, either Flna or Flnb deficiency causes severe distinct developmental malformations in genetic mouse models.16-20 In humans, mutations of either isoform associate with severe genetic diseases, indicating that FLNA and FLNB have equally distinguished biological functions and cannot completely compensate each other during organ development.5 In contrast to the intensive research efforts on the tumor biology of FLNA, the functions of FLNB in tumor cell signaling and growth are barely explored. Hence, it is becoming urgent to study the role of FLNB in tumor development to get a
comprehensive understanding of FLNs in tumors and provide a potential diagnostic and therapeutic usage of FLNs.

The goal of this study is to investigate the role of FLNB in local growth and metastasis during tumorigenesis. Using inoculation of H-RAS-transformed Flnb-deficient mouse embryonic fibroblasts (MEFs), we report that Flnb-deficient tumor cells gained enhanced capability to form larger tumors in mice and to disseminate in zebrafish embryo bodies. The Flnb-deficient tumors also displayed more angiogenic structures. This suggests that FLNB actually plays a suppressive role in tumor progression.

RESULTS

Flnb deficiency promotes tumor growth and metastasis

Rapid tumor growth and enhanced metastasis are the two major characteristics in tumor progression. To study the role of FLNB in tumor growth, we transformed Flnb+/+ and Flnb−/− MEF with H-RAS oncogene. The level of transformed H-RAS was similar between all Flnb+/+ and Flnb−/− MEF clones and one representative clone was illustrated (Figures 1a and b). Both H-RAS-transformed (H-RAS−) Flnb+/+ and Flnb−/− cells proliferate faster than wild-type controls (Flnb+/+H-RAS+), indicating that H-RAS transformation induced cell proliferation (Figure 1c). In addition, the rate of proliferation was faster in Flnb−/− H-RAS− cells than in Flnb+/+H-RAS+ cells. We have then inoculated the oncogenic Flnb+/+ and Flnb−/− MEF into severe combined immunodeficient (SCID) mice. The tumor volume was periodically measured for up to 13 days. Remarkably, Flnb−/− tumors stopped growing after 7 days of inoculation, whereas Flnb+/+ tumors continuously grew over time and were more than two fold larger than Flnb+/+ tumors at day 13 (Figure 1d). To assess the effect of FLNB deficiency on tumor metastasis, we adopted a recently developed metastatic model in zebrafish that allows analysis of tumor cell dissemination at the single-cell level.21 Fluorescently labeled H-RAS-transformed Flnb+/+ and Flnb−/− MEF were implanted into the perivitelline cavity of 48 h post fertilized zebrafish embryos. The tumor cells and foci that were disseminated into head/trunk and tail regions of zebrafish embryos were assessed 6 days after implantation (Figures 2a–d). Implantation of Flnb+/+ MEF led to a significantly higher number of disseminated cells and foci in zebrafish embryos (Figure 2e), indicating that Flnb deficiency leads to increased cell metastasis.

FLNB attenuates phorbol ester-induced MMP-9 expression and activity in fibroblasts

FLNA has been previously reported to suppress the production of either MMP-9 or MMP-2,22 the essential factors in tumor metastasis. To determine whether the induced metastasis in Flnb-deficient tumor cells is related to extracellular matrix degradation, we analyzed the expression and proteolytic activity of MMP-9 and MMP-2 in Flnb+/+ and Flnb−/− MEFs. Serum-starved Flnb+/+ and Flnb−/− MEFs were treated with or without phorbol myristate acetate (PMA), a tumor promoter that is known to induce MMP expression. The expression of Mmp9 in both Flnb+/+ and Flnb−/− MEFs was significantly induced by PMA. However, the response to PMA induction in the expression of Mmp9 was higher in Flnb−/− MEF than in Flnb+/+ MEFs (Figure 3a). In contrast, the mRNA expression of Mmp2 was not induced by PMA in either Flnb+/+ or Flnb−/− MEFs (Figure 3b), suggesting FLNB differentially regulates expression of Mmp9 and Mmp2 at the mRNA level in MEFs.

The proteolytic activity of MMP-9 and MMP-2 was analyzed by gelatin zymography. Consistent with the mRNA expression, the baseline proteolytic activity of MMP-9 and MMP-2 showed similar levels between Flnb+/+ and Flnb−/− MEFs. However, Flnb deficiency significantly enhanced PMA-induced proteolytic activity of MMP-9 in Flnb−/− cells, but not in Flnb+/+ cells (Figure 3c). Similar to the unchanged expression of Mmp2 mRNA, the proteolytic activity of MMP-2 was not regulated by PMA in either Flnb+/+ or Flnb−/− MEFs (Figure 3d).

To assess the functional importance of increased activity of MMP-9, we analyzed the invasion capability of Flnb+/+ and Flnb−/− MEFs stimulated with or without PMA in a matrigel invasion assay (Figure 3e). The number of invaded Flnb−/− MEFs was significantly

![Figure 1](image_url)
increased in response to PMA as compared with response of Flnb+/+ MEFs to PMA.

Induction of MMP-9 in Flnb−/− MEFs and tumors is mediated by the MAPK cascade

One important pathway that responds to extracellular stimuli and regulates MMP-9 expression is the mitogen-activated protein kinase (MAPK) cascade. Among the subgroups of the MAPK cascade, the extracellular signal-regulated kinase-1/2 (ERK1/2) signaling pathway is preferentially activated in response to growth factors and PMA. To assess whether the MAPK cascade was differentially affected by PMA stimulation between Flnb+/+ and Flnb−/− MEFs, the activation of RAS-GRF, various PKC isoforms and ERK1/2 was examined by immunoblotting (Figure 4a). Flnb−/− MEFs displayed increased levels of RAS-GRF, and phosphorylated ERK1/2 in response to PMA stimulation (Figure 4a). Levels of FLNA protein were not different between Flnb+/+ and Flnb−/− MEFs with or without PMA stimulation, indicating that FNLA expression was not altered to compensate for the lack of FLNB in our cellular model (Figure 4a).

In the MAPK cascade, MAPK kinase (MEK) directly phosphorylates ERK1/2 and leads to its activation. To determine whether the proteolytic activity of MMP-9 was dependent on ERK1/2 phosphorylation (Figure 4b). Pretreatment with this inhibitor abolished the PMA-induced MMP-9 activity in Flnb−/− MEFs (Figure 4c), whereas the proteolytic activity of MMP-2 was not affected (data not shown).

In agreement with our in vitro study, the remarkably increased tumor growth in Flnb−/− tumors was associated with significantly induced MMP-9 production and ERK activation in vivo (Figures 4d and e). These results suggest that the increased invasion capability in vitro and the enhanced metastasis in vivo of Flnb-deficient tumor cells are likely mediated by MAPK/ERK cascade-regulated MMP-9 expression.

FLNB suppresses MMP-9 expression in endothelial and tumor cells

To validate our finding in MEFs that FLNB suppresses MMP-9 expression is ubiquitous, we evaluated MMP-9 expression or proteolytic activity in either primary embryonic endothelial cells (ECs) isolated from Flnb+/+ and Flnb−/− mice or human tumor cells with targeted FLNB silencing by FLNB small hairpin RNA (shRNA). Mmp9 mRNA levels were significantly increased in Flnb−/− ECs in normal culture condition with serum, indicating that FLNB constitutively suppresses Mmp9 expression (Figure 5a). Moreover, transient FLNB silencing in M2 human melanoma cells (Figure 5b) resulted in a significant increase in Mmp9 mRNA expression (Figure 5c), further excluding the possibility that increased MMP9 expression is because of a developmental compensation for FLNB deficiency. FLNA has been previously reported to decrease MMP-9 expression in human melanoma cells. Thus, our finding in FLNA-deficient M2 cells suggested that the suppressive effect of FLNA and FLNB on MMP-9 expression is synergic, although in some cases the two FLN isoforms can compensate for each other functionally. Furthermore, the proteolytic activity of MMP-9 was significantly increased when FLNB was silenced in human ovarian cancer cells (Figures 5d and e) that is associated with enhanced cancer cell invasion (Figure 5f).

Flnb deficiency enhances tumor angiogenesis and induces VEGF-A secretion that is likely mediated by the MAPK cascade

Tumors induce angiogenesis by secreting growth factors including VEGF-A that is a fundamental step in the malignant transformation of tumors. We assessed capillary structurues in tumors formed from H-RAS-transformed Flnb+/+ and Flnb−/− MEFs in SCID mice. The
Figure 3. Increased expression of Mmp9 mRNA and MMP-9 proteolytic activity in MEFs deficient for FLNB. Semi-quantitative analysis of Mmp9 (a) and Mmp2 (b) mRNA in wild-type (Flnb+/+) and Flnb-deficient (Flnb−/−) MEFs as detected by reverse transcrip-tase–PCR (RT–PCR) and normalized to 18S mRNA. Cells were serum starved and treated with or without PMA. Representative images of gel electrophoresis are shown. Quantification of the proteolytic activity of MMP-9 (c) and MMP-2 (d) in cell culture medium by gelatin zymography. Representative images of zymography. (e) Invasion of Flnb+/+ and Flnb−/− MEFs in response to PMA stimulation. Flnb+/+ and Flnb−/− MEFs were cultured with PMA in serum-starved conditions and assayed for cell invasion through a Matrigel-coated Boyden chamber. Fold changes in the number of cells invaded through the Matrigel-coated membrane. Data of triplicated experiments are expressed as mean ± s.d. *P < 0.05; **P < 0.01 versus non-PMA-treated respective MEFs; #P < 0.05 versus PMA-treated MEFs.

Flnb−/− tumors displayed an obviously different morphology compared with Flnb+/+ tumors. The number of vasculatures was increased whereas the vasculature network was more disorganized in Flnb−/− tumors (Figure 6a). Correspon-dingly, the Flnb−/− tumors secreted significantly higher levels of VEGF-A than Flnb+/+ tumors (Figure 6b). To assess whether this induced VEGF-A secretion is mediated by the MAPK cascade, we measured secreted VEGF-A in cultured medium of H-RAS-transformed Flnb−/− and Flnb+/+ MEFs. Flnb−/− MEFs secreted more VEGF-A and their secretion of VEGF-A was more remarkably enhanced upon PMA treatment compared with Flnb+/+ MEFs. However, the addition of MAPK inhibitor significantly decreased the secretion of VEGF-A in these cells, indicating that the majority of induced VEGF-A was mediated by the MAPK pathway (Figure 6c).

Flnb silencing in tumor cells induces VEGF-A secretion and in vitro angiogenesis

In agreement to our finding in H-RAS-transformed MEFs, silencing of FLNB in human ovarian cancer cells also significantly induced the secretion of VEGF-A (Figure 6d). Importantly, the conditioned medium collected from FLNB-silenced ovarian cancer cell cultures significantly promoted the formation of vasculature-like circular structures of porcine aortic endothelial cells in a matrigel angiogenesis assay compared with normal ovarian cancer cell culture medium (Figure 6e). These results provide further evidence that FLNB suppresses VEGF-A secretion in tumors that could regulate the angiogenic process.

DISCUSSION

In contrast to the stimulatory role of FLNA in tumor progression, we surprisingly found that the absence of FLNB actually promotes tumor growth. Our study revealed that the induced progression of Flnb-deficient tumors is likely mediated by increased metastasis and angiogenesis. We further explored the molecular mechanism that the enhanced tumor metastasis and angiogenesis may be mediated by an MAPK/ERK pathway-dependent increase in MMP-9 expression and VEGF-A secretion in Flnb-deficient tumor cells. This unanticipated finding suggests a differential role of FLNA and FLNB in tumor development.

FLNs are widely considered to be crucial for cell motility by either directly modulating the actin cytoskeleton or scaffolding for other signaling molecules. FLNA-deficient human melanoma cells and Flnb+/+ MEFs exhibit remarkably reduced cell migration.18 In contrast to our current understanding of the role of FLNs in cell migration, Flnb−/− tumor cells displayed enhanced metastasis in our zebrafish model. Flnb−/− tumor cells also displayed enhanced invasive capability in vitro. Cell metastasis and invasion is a complex process that involves both cell migration and degradation of the extracellular matrix. Interestingly, FLNA-deficient melanoma cells and megakaryocytes displayed an increased expression and activity of MMP-9.22,23 Contradictory to these studies, a recent report showed that both FLNA and FLNB knockdown activated MMP-2 but not MMP-9 in human fibrosarcoma cells, leading to enhanced extracellular matrix degradation.24 We found that expression of MMP-9 was induced in Flnb−/− mouse fibroblasts and ECs, and in FLNB-knockdown human melanoma and ovarian cancer cells. The discrepancy between the different effects on MMPs by FLNs might be cell-type specific. For example, in contrast to human melanoma cells where the proteolytic activity of MMP-2 is very low, the proteolytic activity of MMP-2 was markedly higher than MMP-9 in both Flnb+/+ and Flnb−/− MEFs in our study. This indicates that the expression of MMP-2 and -9 have differential regulation in a cell-type-specific manner. The differences can be linked to the promoter elements of Mmp2 and Mmp9. The promoter of Mmp9 is similar to most other MMPs, whereas the MMP-2 promoter lacks many of the
inducible promoter elements such as binding sites for the AP-1 and ETS transcription factors. Nevertheless, these findings raise an important issue that cell metastasis may be dependent on the balance between cell motility and MMP expression and activity that are regulated by FLNs. Although most of the studies point to a positive correlation between expression of FLNA and metastasis in cancers, two recent studies showed that FLNA expression is negatively correlated with the malignancy of breast cancer lines. This is probably because of the suppression of FLNA on breast cancer cell migration and invasion. It is interesting that FLNA-deficient cells show reduced migration, but induced expression of MMPs. This also makes it complicated to predict the final effect on tumor metastasis.

We and others have found that in vivo Fina deficiency caused tumor growth in lung cancer and other cancers. This indicates that reduced cell migration may overcome the overexpression of MMPs in certain Fina-deficient tumor cells. However, in a metastasis assay, Flnb-deficient tumor cells displayed enhanced spreading of tumor cells. It still requires further investigation regarding how the similar phenotypes of FLNA- and FLNB-deficient cells display opposite outcomes in vivo. Nevertheless, our findings may reflect a dual role of FLNs in tumor invasion: in one aspect, FLNs are critical for cell migration and deficiency of FLNs may impair tumor invasion; in another aspect, FLNs inhibit MMP activity that may suppress tumor invasion. The dual role of FLNs in tumor invasion may depend on the stages of tumor progression or work coordinately in regulating tumor metastasis.

Tumor growth is highly dependent on angiogenesis for sufficient blood flow supply. In the absence of angiogenesis, tumor implants do not grow beyond 2 to 3 mm³ and enter into a dormant state. We found that Fnb-deficient tumors secrete more VEGF-A and display enhanced angiogenesis that likely accounts for the continuous growth of Fnb-deficient tumors compared with the Fnb-expressing tumors.

Figure 4. The MAPK cascade mediates PMA-induced MMP-9 proteolytic activity in cells deficient for FLNB. (a) Representative immunoblots detecting protein levels of FLNB, RAS-GRF, phosphorylated PKC-α/β, total PKC-δ, phosphorylated ERK1/2, total ERK1/2 and FLNA in serum-starved Flnb+/+ and Flnb−/− MEFs after induction with or without PMA for 15 min. Actin served as an internal loading control. (b) Representative immunoblot demonstrating the inhibition of p-ERK1/2 expression in Flnb−/− cells induced with PMA and pretreated with PD 098059, a MAPK inhibitor. *P < 0.05 versus non-pretreated MEF with PD 098059. (c) Gelatin zymography detecting proteolytic activity of MMP-9 in cell culture medium of Flnb−/− MEFs pretreated with PD 098059, and then cultured in serum-starved conditions with PMA. (d) Immunoblots for pro-MMP-9, MMP-9, p-ERK1/2 and total ERK1/2 proteins extracted from Flnb−/− H-RAS+ and Flnb+/+ H-RAS+ tumors. Actin served as an internal loading control. (e) Densitometric reading of MMP-9 and p-ERK1/2 proteins are given as fold differences. Data of triplicate or quadruplicate experiments are expressed as mean ± s.d. *P < 0.05; ***P < 0.001 versus non-PD 098059-treated MEFs or Flnb+/+ H-RAS+ tumors.
angiogenesis is a highly integrated system involving the secretion of angiogenic factors by malignant tumor cells, causing ECs to proliferate, migrate and sprout in response.1 The impact of FLNs on angiogenesis has been recently revealed by findings that ECs display reduced migratory and angiogenic activity after FLNA or FLNB silencing.29,30 This supports our previous findings that EC-specific deficiency of FLNA reduces subcutaneous fibrosarcoma growth and vascularity within tumors.15 However, in the mouse model using tumor inoculation that we used in this study, the ECs are derived from the wild-type host mice. Thus, the increased angiogenesis in Flnb-deficient fibrosarcomas is likely because of the altered production of angiogenic factors from Flnb-deficient tumor cells. In our study, we found that Flnb-deficient mouse fibrosarcoma cells and FLNB-knockdown human ovarian cancer cells secrete more VEGF-A. This provides a potential mechanistic explanation for enhanced angiogenesis in Flnb-deficient tumors. In contrast to FLNB in this study, we recently identified hypoxia-inducible factor-1α as an interacting partner of FLNA, and absence of FLNA in melanoma cells leads to significantly reduced VEGF-A secretion.31 In contrast to FLNB in this study, FLNA-deficient tumor cells secrete significantly less level of VEGF-A. A brief clinical report identified that the expression of FLNA positively correlates with the VEGF-A level in human lung tumors.32 This implies that FLNA may positively regulate VEGF-A production. Further investigation is required to clarify whether FLNA and FLNB regulate VEGF-A production through different pathways or deficiency of FLNB may actually release FLNA from their heterodimer structure, thus enhancing the activity of FLNA in this particular scenario.

Cytokines and growth factors that activate MMP-9 expression typically act via the MAPK cascade including the ERK1/2 signaling pathway.25 Our study showed that PMA-induced activation of ERK1/2 was lower in Flnb−/− MEFs, suggesting that FLNB suppresses the ERK1/2 signaling pathway and thus leads to less expression of MMP-9. PMA is a direct activator of PKC proteins that are upstream in the MAPK cascade. PMA-stimulated expression of MMP-9 was abolished in Flnb−/− MEFs, indicating that FLNB may interfere with protein kinase C (PKC) activity. PKC is a family of protein kinases consisting of conventional (PKC-α, β1, β2 and γ), novel (PKC-δ, ε, η and θ) and atypical (PKC-ζ, η and ζ) isoforms.26 Expression of both PKC-α/β and PKC-ζ/δ is induced by PMA in Flnb−/− MEFs, but not in Flnb+/+ MEFs. This implicates a broad function of FLNB in regulating the activity of both conventional and novel PKCs. In spite of FLNB, FLNA can physically associate with PKC-θ and is required for translocation of PKC-θ from the cytosol to the cell membrane.33 It has also been found that FLNA, but not FLNB, is a ligand and in vivo substrate for PKC-α.34 This indicates that the intimate interaction between FLNs and PKC is both FLN and PKC isoform dependent. The association of FLNB and PKC-θ depends on FLNB and PKC isoform specificity. The proteolytic activity of MMP-9 is not only regulated at the gene expression level. The secretion, pro-enzyme activation and presence of specific inhibitors can all regulate its proteolytic activity.

**Figure 5.** Increased MMP9 mRNA expression in vascular endothelial and tumor cells in the absence of FLNB. (a) Mmp9 mRNA expression in mouse embryonic filamin B-deficient (Flnb−/−) ECs as compared with wild-type (Flnb+/+) ECs as detected by reverse transcriptase-PCR (RT-PCR). (b) FLNB protein expression in human melanoma M2 cells as detected by immunoblot after transfection with vector expressing FLNB shRNA. Immunoblot with Actin served as loading controls. Transfection with GFP shRNA was included as a negative control. (c) Increased mRNA expression of Mmp9 in Flnb−/− silenced M2 cells. (d) FLNB protein expression in OVSCR8 cells transfected with FLNB shRNA, whereas same cells transfected with GFP shRNA served as negative controls. (e) Proteolytic activity of MMP-9 in human ovarian cancer OVSCR8 cells following transfection with FLNB or GFP shRNA. (f) Invasion of OVSCR8 cells after transfection with FLNB or GFP shRNA. Data of triplicated experiments are expressed as mean ± s.d. *P < 0.05; ***P < 0.001 versus respective controls.
However, the proteolytic activity of MMP-9 in function of MMPs in vivo regulatory level of MMP-9 activity by FLNB. Furthermore, the plasminogen activators. This may represent another potential by other activated MMPs or serine proteinases including the zymogen into an active proteolytic enzyme that is mediated Another key step in regulating MMP activity is the conversion of the secretion of MMP-9 by regulating transportation vesicles. processes in MMP-9 activation are also involved. FLNB may affect not regulated by PMA whatsoever. This indicates that other (Supplementary Table S2). In summary, our unanticipated could explain why FLNB is upregulated in some types of cancer the role of FLNB in these types of cancer. Other roles of FLNB affected tumor cell signaling remain to be investigated to assess Supplementary Table S1). Protein expression levels and the mRNA is downregulated in human colorectal and ovarian cancer, melanomas and gastrointestinal sarcomas (www.oncomine.org, melain in tumor growth (et al. 2013). Analysis of FLNB expression in cancer cohorts shows that FLNB activity.35 Mmp9 mRNA levels in Flnb+/+ and Flnb−/− MEFS were both significantly induced upon PMA stimulation, despite Flnb−/− MEFS showing a much higher induction than Flnb+/+ MEFS. However, the proteolytic activity of MMP-9 in Flnb+/+ MEFS was not regulated by PMA whatsoever. This indicates that other processes in MMP-9 activation are also involved. FLNB may affect the secretion of MMP-9 by regulating transportation vesicles. Another key step in regulating MMP activity is the conversion of thezymogen into an active proteolytic enzyme that is mediated by other activated MMPs or serine proteinases including plasminogen activators. This may represent another potential regulatory level of MMP-9 activity by FLNB. Furthermore, the function of MMPs in vivo also depends on the local balance between them and their physiological inhibitors, such as the tissue inhibitors of MMPs. Analysis of FLNB expression in cancer cohorts shows that FLNB mRNA is downregulated in human colorectal and ovarian cancer, melanomas and gastrointestinal sarcomas (www.oncomine.org, Supplementary Table S1). Protein expression levels and the affected tumor cell signaling remain to be investigated to assess the role of FLNB in these types of cancer. Other roles of FLNB could explain why FLNB is upregulated in some types of cancer (Supplementary Table S2). In summary, our unanticipated findings suggest a differential role of FLNB in tumor development. In contrast to its homolog protein FLNA, FLNB negatively regulates tumor progression by suppressing local growth, angiogenesis and metastasis. Our findings point to the need for delicately designed approaches to target FLNs in tumor diagnosis, progression and treatment.

**MATERIALS AND METHODS**

**Cell cultures**

Three different clones of wild-type (Flnb+/+) or homozygous Flnb−/− MEFS were extracted and cultured as described earlier.18 VEGF2-expressing porcine aortic endothelial cells and OVSCR8 cells were cultured in Ham F12 medium and Dulbecco’s modified Eagle’s medium, respectively, and were supplemented with 10% of fetal bovine serum, 1 × penicillin/streptomycin, 1 × nonessential amino acids and 1 × glutamine at 37°C in 5% CO2 cell culture incubators. M2, a human melanoma cell line lacking both FLNA mRNA and protein, were cultured as described earlier.16

**Chemicals**

PMA (Sigma-Aldrich, St Louis, MO, USA) and PD 098059 (Sigma Aldrich), a specific inhibitor of MAPK, were used in cell culture studies.

**Reverse transcriptase–PCR**

Overnight serum-starved MEFS were treated with or without PMA for 6 h. Total RNA from embryonic endothelial cells was isolated at E10.5 as described earlier.18 The total RNA was isolated by RNeasy mini kit following the manufacturer’s instructions (Qiagen Inc., Valencia, CA, USA). The RNA concentration was measured by an Epoch spectrophotometer (Bio-Tek Instruments, Winooski, VT, USA). Complementary DNA was synthesized from 1 μg RNA by the qScript cDNA synthesis kit (Quanta BioSciences, Inc., Gaithersburg, MD, USA). The gene sequences were obtained from National Center for Biotechnology Information (NCBI) and primers were designed by using the primer design tool provided by NCBI ( Primer- Blast, Bethesda, MD, USA). The forward primer 5′-GGCTCAGAAGTCTGCTCCGAC and reverse primer 5′-GGGTCAGATCCAGCGAGTAC for Flnb, 5′-TTGGCAACCATGATCCCGG-3′ and reverse primer 5′-GTGGCCACGCAAGGACC-3′ for Mmp2 and forward primer 5′-AGACCGGCAACGGAGAACG-3′ and

---

**Figure 6.** Increased intratumor vascularity because of increased VEGF-A secretion in Flnb-deficient tumors in vivo. (a) Micrographs of vascular networks within mouse tumors formed by H-RAS-transformed MEFs. Red color represents PECAM-positive endothelial cells (scale bar, 100 μm). (b) Secreted levels of VEGF-A in mouse H-RAS-transformed wild-type (Flnb+/+H-RAS+) or homozygous Flnb-deficient (Flnb−/−H-RAS+) tumors. (c) Secreted levels of VEGF-A in wild-type (Flnb+/+) and homozygous Flnb-deficient (Flnb−/−) MEFs treated without reagent (Ø), PMA or MAPK inhibitor. (d) Secreted levels of VEGF in OVSCR8 cells following transfection with FLNB or GFP shRNA. (e) Representative image and quantification of circular vascular structures of porcine aortic endothelial (PAE) cells after conditioning with conditioned medium from FLNB or GFP shRNA-transfected OVSCR8 cells. Data of triplicate or quadruplicate experiments are expressed as mean ± s.d. *P < 0.05, **P < 0.01 and ***P < 0.001 versus respective controls.
Transformations

Three different clones of wild-type (Flnb<sup>+/+</sup>) or homozygous Flnb-deficient (Flnb<sup>−/−</sup>) MEFs were transformed with pLXSP3+Human H-RAS (Val12) plasmid expressing H-RAS.<sup>11</sup> All these clones were tested for mRNA expression of Mmp9 and levels of active RAS. The transformed cells were selected by growing them in antibiotic medium for 2–3 weeks. RAS activity was determined by active RAS pull-down assay (Thermo Fisher Scientific, Waltham, MA, USA).

Tumor cell inoculations

CB17/scid/Prkdc<sup>−/−</sup>/Crl SCID male mice (Charles River Laboratories International, Inc., Wilmington, MA, USA), 5 to 6 weeks old, were injected subcutaneously with 3 × 10<sup>6</sup> H-RAS-transformed Flnb<sup>−/−</sup> MEFs as control group (<i>n</i> = 12) and Flnb<sup>−/−</sup> MEFs as test group on the dorsal back region as described earlier.<sup>10</sup> Tumors were carefully harvested, weighed, frozen in liquid nitrogen and stored in −80 °C. All the mouse experiments were approved by the local animal ethical committee.

Zebrafish model of tumor inoculation

A transgenic zebrafish strain expressing enhanced green fluorescent protein (EGFP) under the <i>flb</i> promoter (flb:EGFP) was used as described earlier.<sup>21</sup> Invasion and dissemination of the tumor cells were investigated 6 days post implantation with a fluorescent microscope (Nikon Instruments Inc., Melville, NY, USA).

Gelatin zymography

Flnb<sup>+/+</sup> and Flnb<sup>−/−</sup> MEFs were grown arrested by being cultured in serum-free medium overnight. Flnb<sup>+/+</sup> and Flnb<sup>−/−</sup> MEFs were transfected with pLXSP3+Human H-RAS (Val12) plasmid expressing H-RAS.<sup>11</sup> All these clones were then cultured in 2% agarose gel electrophoresis and quantified by densitometry reading. 185 RNA was used as an internal loading control for quantification.

Immunoblotting

MEFs were cultured with or without PMA in serum-starved condition overnight. Flnb<sup>+/+</sup> and Flnb<sup>−/−</sup> tumor tissues were homogenized and immunoblotted as described earlier,<sup>19</sup> followed by incubation with primary antibody against FLNB (Chemicon International, Inc., Temecula, CA, USA); FLNB (EMD Millipore, Billerica, MA, USA). The enzymatic activity of MMP-9 and MMP-2 was measured by gelatin zymography (Life Technologies, Carlsbad, CA, USA) following instructions provided by the manufacturer. Briefly, after electrophoresis, gels were incubated with 1 × renaturation buffer for 30 min followed by overnight incubation in developing buffer at 37 °C. The bands were visualized by simple blue stain for 1 h and destained with distilled water for 1–3 h. The presence of enzyme activity was confirmed by the appearance of white bands on blue background.

Fluorescence-activated cell sorting

The shRNA-transfected cells were harvested after 72 h, diluted with 0.5% fetal bovine serum in phosphate-buffered saline and analyzed with fluorescence-activated cell sorting (BD Biosciences). GFP-negative cells were discharged after sorting, and the sorted GFP-positive cells were cultured overnight and were used for experiments the next day.

Enzyme-linked immunosorbent assay

Conditioned medium was collected from cell cultures of wild-type (Flnb<sup>+/+</sup>) or homozygous Flnb-deficient (Flnb<sup>−/−</sup>) MEFs, H-RAS-transformed Flnb<sup>+/+</sup>, Flnb<sup>−/−</sup> MEFs and human ovarian cancer cells (OVSCR-8) assayed for VEGF-A protein according to the manufacturer’s protocol (R&D Biosystems, Inc., Minneapolis, MN, USA). VEGF-A levels were measured by an Epoch spectrophotometer (Bio-Tek Instruments).

Matrigel assay

Porcine aortic endothelial cells expressing VEGFR2 were cultured in precoated 24-well plates with Matrigel (BD Biosciences). The cells were cultured until reaching ~50–60% confluency and then conditioned with a mixed medium containing 80% of 2% fetal bovine serum Ham f12 and 20% OVS8CR cell-conditioned medium. The cells were incubated at 37 °C with 5% CO2 for 24 h and were fixed with 4% paraformaldehyde for 30 min at room temperature and permeabilized with phosphate-buffered saline with Tween (PBST) 0.01 Triton X-100 for 30 min. Cells were stained with phallolidin (Life Technologies) for 1 h at room temperature followed with 3 washing steps for 10 min. Circular formed structures were photographed (Nikon Instruments Inc.) and counted at five optical fields (10×) for each well.

Conflicts of Interest

The authors declare no conflict of interest.

Acknowledgements

This work was supported by The Swedish Society of Medicine, The Magnus Bergvall’s Foundation, Jubileumfonden, The Sahlgrenska University Hospital, The Royal Society of Arts and Sciences in Göteborg, The Assar Gabrielsson’s Foundation, The Swedish Heart and Lung Foundation, The Swedish Research Council and The Swedish Cancer Foundation.

References

1. Cao Y, Arbiser J, D’Amato RJ, D’Amore PA, Ingber DE, Kerbel R et al. Forty-year journey of angiogenesis translational research. Science Transl Med 2011; 3: 114rv113.
2. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signalling and relationship to tumor progression. Biochim Bioph Acta 2012; 1825: 29–36.
3. Stoskop TP, Condeelis J, Cooley L, Hartwig JH, Noegel A, Schleicher M et al. Filamins as integrators of cell mechanics and signalling. Nat Rev Mol Cell Biol 2001; 2: 138–145.
4. Zhou X, Boren J, Akyürek LM. Filamins in cardiovascular development. Trends Cardiovasc Med 2007; 17: 222–229.
5. Zhou AX, Hartwig JH, Akyürek LM. Filamins in cell signalling, transcription and organ development. Trends Cell Biol 2010; 20: 113–123.
6. Guedj N, Zhan Q, Perigny M, Rautou PE, Degas F, Belghiht J et al. Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas. J Hepatol 2009; 51: 93–101.
